Intervacc AB (publ) (STO:IVACC)

Market Cap	381.03M
Revenue (ttm)	13.97M
Net Income (ttm)	-71.30M
Shares Out	340.81M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	483,746
Average Volume	422,911
Open	1.080
Previous Close	1.118
Day's Range	1.064 - 1.144
52-Week Range	0.729 - 3.810
Beta	0.60
RSI	60.27
Earnings Date	Aug 29, 2025

About CTI BioPharma

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 15
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IVACC

Financial Performance

In 2024, Intervacc AB's revenue was 11.79 million, an increase of 46.84% compared to the previous year's 8.03 million. Losses were -75.52 million, -26.58% less than in 2023.